This document discusses a study on the use of human umbilical cord mesenchymal stem cells (hucMSCs) for renal therapy. The study isolated and identified hucMSCs and injected them into a cisplatin-induced acute kidney injury rat model. The results showed that hucMSCs accelerated renal recovery, promoted proliferation and inhibited apoptosis of renal tubular cells, and protected renal cell mitochondria from dysfunction. Additionally, hucMSCs inhibited renal interstitial fibrosis and epithelial-mesenchymal transition in renal cells. The conclusion is that hucMSCs attenuated cisplatin-induced acute and chronic renal injury by preventing mitochondrial dysfunction and suppressing epithelial-mesenchymal transition development.

1. Human umbilical cord mesenchymal
stem cells based renal therapy

2. INTRODUCTION

3. MATERIALS AND METHODS
hucMSCs isolation and identification
CM-Dil cell-labelling
Cell co-culture
Cisplatin-induced renal injury rat model (6.0 mg/kg)
hucMSCs transplantation (intraperitoneally injection)
Renal function and Malondialdehyde (MDA) determination
Histopathology and Masson’s trichrome staining
TUNEL staining and immunohistochemistry
Quantitative RT-PCR
Western blot

4. hucMSCs accelerate the recovery of renal function in cisplatin-induced
AKI rats
●

5. hucMSCs promote proliferation of and inhibit
apoptosis and alleviate inflammation in cisplatin-induced
AKI rats in the renal tubular cells of cisplatin-induced
AKI rats

6. hucMSCs protect renal cell mitochondria from
dysfunction and inhibit the activation of mitochondrial
apoptosis signaling

7. Effects of hucMSCs on rat renal function indexes and histology

8. Inhibition of renal interstitial fibrosis by hucMSC injection

9. hucMSCs inhibit epithelial-mesenchymal transition in
renal cells in vivo and in vitro

10. Conclusion
In conclusion,results demonstrate that hucMSCs attenuate cisplatin-induced acute
and chronic renal injury through preventing mitochondria dysfunction, inhibiting
the activation of mitochondrial signaling pathway and suppressing the
development of EMT.
These findings suggest that hucMSC transplantation is a useful approach for the
therapy of cisplatin-induced AKI and the subsequent renal interstitial fibrosis.